secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0000805928-25-000128
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen Q3 revenue $60.1M (+23.5% YoY); raises FY revenue guidance to at least $222.8M
--------------------------------------------------------------------------------

- Net income of $0.7M ($0.01 EPS) vs net loss of $1.9M in Q3 2024; adjusted EPS $0.12 vs $0.07.
- Gross margin improved to 76.6% from 74.9% YoY; adjusted EBITDA $9.2M vs $6.5M.
- Raised full-year revenue guidance to at least $222.8M (≥19% growth); gross margin reaffirmed 73-75%.
- FDA PDUFA for Avance Nerve Graft BLA extended to Dec 5, 2025; AAHS and ASRM issued position statements recognizing nerve allografts.
- Added 18.1M covered lives in 2025; commercial payer coverage now over 64%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592825000128/0000805928-25-000128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592825000128/axgn-20251029.htm
  HTML page:      https://secwatch.observer/filing/0000805928-25-000128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer